Glen Eagle Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $608K | Sell |
21,653
-2,406
| -10% | -$64.1K | 0.09% | 156 |
|
|
2025
Q4 | $599K | Sell |
24,059
-7,964
| -25% | -$201K | 0.08% | 163 |
|
|
2025
Q3 | $816K | Buy |
32,023
+6,624
| +26% | +$163K | 0.11% | 122 |
|
|
2025
Q2 | $616K | Buy |
25,399
+730
| +3% | +$17K | 0.09% | 134 |
|
|
2025
Q1 | $625K | Sell |
24,669
-5,193
| -17% | -$136K | 0.1% | 129 |
|
|
2024
Q4 | $792K | Buy |
29,862
+5,796
| +24% | +$157K | 0.13% | 110 |
|
|
2024
Q3 | $696K | Sell |
24,066
-2,902
| -11% | -$84.7K | 0.12% | 120 |
|
|
2024
Q2 | $755K | Sell |
26,968
-10,979
| -29% | -$302K | 0.14% | 108 |
|
|
2024
Q1 | $1.05M | Sell |
37,947
-5,260
| -12% | -$146K | 0.2% | 94 |
|
|
2023
Q4 | $1.24M | Sell |
43,207
-7,777
| -15% | -$235K | 0.26% | 80 |
|
|
2023
Q3 | $1.69M | Sell |
50,984
-273
| -0.5% | -$9.65K | 0.39% | 55 |
|
|
2023
Q2 | $1.88M | Buy |
51,257
+5,198
| +11% | +$202K | 0.43% | 53 |
|
|
2023
Q1 | $1.88M | Buy |
46,059
+2,547
| +6% | +$110K | 0.47% | 49 |
|
|
2022
Q4 | $2.23M | Sell |
43,512
-441
| -1% | -$21.1K | 0.61% | 38 |
|
|
2022
Q3 | $1.92M | Sell |
43,953
-8,634
| -16% | -$420K | 0.56% | 41 |
|
|
2022
Q2 | $2.76M | Buy |
52,587
+5,514
| +12% | +$281K | 0.75% | 35 |
|
|
2022
Q1 | $2.44M | Sell |
47,073
-99
| -0.2% | -$5.14K | 0.64% | 39 |
|
|
2021
Q4 | $2.79M | Sell |
47,172
-1,641
| -3% | -$81.3K | 0.72% | 34 |
|
|
2021
Q3 | $2.1M | Buy |
48,813
+2,736
| +6% | +$121K | 0.61% | 40 |
|
|
2021
Q2 | $1.8M | Buy |
46,077
+1,080
| +2% | +$42K | 0.56% | 44 |
|
|
2021
Q1 | $1.64M | Buy |
44,997
+2,825
| +7% | +$100K | 0.57% | 40 |
|
|
2020
Q4 | $1.55M | Sell |
42,172
-1,726
| -4% | -$63.3K | 0.61% | 40 |
|
|
2020
Q3 | $1.53M | Buy |
43,898
+5,020
| +13% | +$176K | 0.68% | 35 |
|
|
2020
Q2 | $1.21M | Buy |
38,878
+20,674
| +114% | +$702K | 0.62% | 38 |
|
|
2020
Q1 | $564K | Buy |
18,204
+4,227
| +30% | +$144K | 0.4% | 58 |
|
|
2019
Q4 | $520K | Buy |
13,977
+2,399
| +21% | +$85.5K | 0.28% | 83 |
|
|
2019
Q3 | $395K | Buy |
11,578
+203
| +2% | +$7.38K | 0.26% | 87 |
|
|
2019
Q2 | $468K | Buy |
11,375
+91
| +0.8% | +$3.61K | 0.32% | 76 |
|
|
2019
Q1 | $455K | Buy |
11,284
+654
| +6% | +$26.2K | 0.33% | 74 |
|
|
2018
Q4 | $440K | Buy |
10,630
+192
| +2% | +$7.97K | 0.37% | 65 |
|
|
2018
Q3 | $436K | Sell |
10,438
-158
| -1% | -$6.08K | 0.31% | 75 |
|
|
2018
Q2 | $365K | Buy |
10,596
+1,614
| +18% | +$55.2K | 0.29% | 80 |
|
|
2018
Q1 | $302K | Buy |
8,982
+850
| +10% | +$29.2K | 0.25% | 91 |
|
|
2017
Q4 | $279K | Buy |
8,132
+438
| +6% | +$14.9K | 0.24% | 98 |
|
|
2017
Q3 | $261K | Sell |
7,694
-2,234
| -23% | -$71.8K | 0.24% | 100 |
|
|
2017
Q2 | $316K | Buy |
9,928
+190
| +2% | +$5.99K | 0.25% | 100 |
|
|
2017
Q1 | $317K | Sell |
9,738
-234
| -2% | -$7.38K | 0.27% | 95 |
|
|
2016
Q4 | $307K | Buy |
+9,972
| New | +$304K | 0.28% | 96 |
|
Other funds holding PFE
VCM
VPM
Glen Eagle Advisors's PFE Position: Q1 2026 in Review
Glen Eagle Advisors reduced its Pfizer (PFE) stake by 10% in Q1 2026, selling an estimated $64.1K and leaving 21,653 shares worth $608K. The position accounts for 0.09% of the portfolio, ranked #156.
Glen Eagle Advisors first reported a position in PFE in Q4 2016 and has held it in 38 quarters since. The position peaked at $2.79M in Q4 2021. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Glen Eagle Advisors held 21,653 shares of Pfizer worth $608K as of Q1 2026.
- Glen Eagle Advisors sold 2,406 Pfizer shares in Q1 2026, an estimated $64.1K.
- Pfizer made up 0.09% of Glen Eagle Advisors's portfolio in Q1 2026, its #156 holding.
- Glen Eagle Advisors first reported a position in Pfizer in Q4 2016 and has held it in 38 quarters since.
- Glen Eagle Advisors's Pfizer position peaked at $2.79M in Q4 2021.
- 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.